Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ALECSAT - CytoVac

Next Previous
Drug Profile

ALECSAT - CytoVac

Alternative Names: ALECSAT

Latest Information Update: 28 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CytoVac
  • Class Cell therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; Immunostimulants; Natural killer cell replacements; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sarcoma; Glioblastoma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Glioblastoma; Sarcoma
  • Phase I/II Triple negative breast cancer
  • No development reported Pancreatic cancer; Prostate cancer

Most Recent Events

  • 28 Jul 2024 No recent reports of development identified for phase-I development in Pancreatic-cancer in Denmark (IV, Injection)
  • 28 Jul 2024 No recent reports of development identified for phase-I development in Prostate-cancer in Denmark (IV, Injection)
  • 23 Jul 2022 Phase I/II development in Triple-negative-breast cancer (Metastatic disease, Adjunctive treatment, Late-stage disease) is ongoing in Denmark (IV) (NCT04609215) (EudraCT2019-001420-34)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top